Results 121 to 130 of about 1,634 (161)
Some of the next articles are maybe not open access.
Pediatric, Allergy, Immunology, and Pulmonology
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in people of all ages and is the leading cause of hospitalization among infants in the United States. The year 2023 was exciting for RSV prevention. The Food and Drug Administration (FDA) approved 3 new tools for preventing severe lower respiratory tract RSV ...
exaly +3 more sources
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in people of all ages and is the leading cause of hospitalization among infants in the United States. The year 2023 was exciting for RSV prevention. The Food and Drug Administration (FDA) approved 3 new tools for preventing severe lower respiratory tract RSV ...
exaly +3 more sources
Practical Application of Nirsevimab Recommendations for Infants and Toddlers
Journal of Pediatric Health CareRespiratory syncytial virus (RSV) is a common respiratory tract infection that causes bronchiolitis and pneumonia in infants and children. It is the leading cause of hospitalization of infants in the United States. Nirsevimab is a long-acting monoclonal antibody recommended for the prevention of severe disease in all infants under 8 months of age and ...
Rebecca Carson
exaly +3 more sources
Formulary Drug Reviews: Nirsevimab
Hospital Pharmacy, 2023Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Terri L. Levien, Danial E. Baker
openaire +2 more sources
Drugs, 2022
Nirsevimab (Beyfortus®), a long-acting intramuscular recombinant neutralising human IgG1ĸ monoclonal antibody to the prefusion conformation of the respiratory syncytial virus (RSV) F protein that has been modified with a triple amino acid substitution in the Fc region to extend the serum half-life, is being jointly developed by AstraZeneca and Sanofi ...
openaire +2 more sources
Nirsevimab (Beyfortus®), a long-acting intramuscular recombinant neutralising human IgG1ĸ monoclonal antibody to the prefusion conformation of the respiratory syncytial virus (RSV) F protein that has been modified with a triple amino acid substitution in the Fc region to extend the serum half-life, is being jointly developed by AstraZeneca and Sanofi ...
openaire +2 more sources
Preventive Paediatrics
Respiratory syncytial virus (RSV) is a dominating respiratory infection worldwide. It is responsible for infecting millions of children worldwide each winter through highly contagious droplets and secretions. Over 2.1 million of these children require some form of medical attention during illness.
Ivana Kalanovic Dylag, Andrew Dylag
openaire +1 more source
Respiratory syncytial virus (RSV) is a dominating respiratory infection worldwide. It is responsible for infecting millions of children worldwide each winter through highly contagious droplets and secretions. Over 2.1 million of these children require some form of medical attention during illness.
Ivana Kalanovic Dylag, Andrew Dylag
openaire +1 more source
Nirsevimab and Hospitalization for RSV Bronchiolitis
New England Journal of MedicineRespiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody against RSV that has an extended half-life. Its postlicensure real-world effectiveness against RSV-associated bronchiolitis is unclear.We conducted a prospective, multicenter, matched ...
Assad, Zein +34 more
openaire +2 more sources
Parent Perspectives on Nirsevimab for Their Newborn
PediatricsBACKGROUND In 2023, nirsevimab, a monoclonal antibody against respiratory syncytial virus (RSV), was approved in the United States to be given to infants to prevent bronchiolitis, a leading cause of pediatric hospitalizations.
Sarah, Hinderstein +2 more
openaire +2 more sources